1-2 of 2
Joel Rothman
Close
Sort by
Journal Articles

Itolizumab, a Novel Targeted Anti-CD6 Therapy, in Combination with Corticosteroids, Is Well-Tolerated, with Rapid Pharmacodynamic and Clinical Response in Newly Diagnosed Acute Graft-Versus-Host Disease

John Koreth, Jerome Ritz, Leslie Chinn, Cherie Ng, Lisette M Acevedo, Dalena Chu, Maple Fung, Joel Rothman, Stephen Connelly, Dolca Thomas, Corey Cutler
Journal: Blood
Blood (2021) 138 (Supplement 1): 2891.
https://doi.org/10.1182/blood-2021-145721
Published: 2021
Journal Articles

Equate, a Phase 1b/2 Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of a Novel Targeted Anti-CD6 Therapy, Itolizumab, in Subjects with Newly Diagnosed Acute Graft Versus Host Disease

John Koreth, MBBS, DPhil, Saurabh Chhabra, MD, Joseph Pidala, MD, Thomas C. Shea, MD, Madan Jagasia, MBBS, MS, MMHC, Edmund K. Waller, PhDMD, Ryotaro Nakamura, MD, Marco Mielcarek, MD, George L. Chen, MD, Gabrielle Meyers, MD, Daanish Hoda, MD, Betty K. Hamilton, MD, Cherie Tracy Ng, PhD MPH, Mark Sonnemann, Susan Light, MD, Nuwan Nanayakkara, PhD, David Essayan, MD, Joel Rothman, BS, Stephen Connelly, PhD MBA, Krishna Polu, MD, Leslie Kean, MD PhD, Jerome Ritz, MD, Robert J. Soiffer, MD, Corey Cutler, MD MPH, FRCPC
Journal: Blood
Blood (2019) 134 (Supplement_1): 4516.
https://doi.org/10.1182/blood-2019-127325
Published: 2019